Vedolizumab study for kids with ulcerative colitis or Crohn’s
Treatments studied
Part of Digestive system clinical trials.
This Phase 3 study tests whether vedolizumab can help children with ulcerative colitis (UC) or Crohn’s disease (CD) who improved on earlier treatment. It focuses on kids who can stay off steroid medicines and follow study visits and safety rules.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have finished an earlier study (MLN0002-3024 or MLN0002-3025) and improved by Week 54 without steroid medicine for at least 12 weeks
- If you (or your partner) could get pregnant, you must agree to reliable birth control during the study and for 18 weeks after the last dose
- If you’re in the treatment group, you should not need major bowel surgery for UC or Crohn’s now or during the study
- You must not have new serious, unstable, or uncontrolled health problems that could affect safety or results
- You must be able to follow all study checkups and tests, and not have a known allergy to vedolizumab ingredients
- You must not be pregnant or breastfeeding
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests vedolizumab, a biologic medicine that reduces inflammation, in children and teenagers who have moderate to severe ulcerative colitis or Crohn's disease and have not responded well to other treatments.
This study is for children and teenagers with ulcerative colitis or Crohn's disease who have already completed a previous vedolizumab study and are doing well. It will look at the long-term safety and effectiveness of continuing vedolizumab treatment.
This study tests a medication called vedolizumab for people with moderate to severe ulcerative colitis or Crohn's disease. The goal is to see how well it works in a regular community setting, and it may help control symptoms if other treatments haven't worked.
This program lets children and teenagers with ulcerative colitis or Crohn's disease continue receiving vedolizumab (a biologic medicine) through an IV if it's already helping them. It's for those who have no better treatment options and want to keep getting the same medicine.
This Phase 3 study tests whether vedolizumab can better control moderate-to-severe Crohn’s disease in adults whose symptoms haven’t improved enough with other treatments. You’d need to meet specific symptom scores, recent colonoscopy findings, and safety checks (including infections and vaccination status).
This study compares two biologic medicines, vedolizumab and infliximab, to see which works better for children with moderate to severe ulcerative colitis. It aims to find a more effective treatment to reduce symptoms and improve quality of life.
Hear when a new Ulcerative Colitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.